Managing Type 2 Inflammation in Chronic Obstructive Pulmonary Disorder with Dupilumab
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on August 12th, 2024
|
The current standard treatment for chronic obstructive pulmonary disorder include glucocorticoids, long-acting muscarinic antagonist (LAMA) and long-acting beta agonist (LABA). In certain cases, disease extraction exacerbation happens even when the maximum dose of the two standard therapy has been administered. Dupilumab is a monoclonal antibody that can dampen type 2 inflammation by interfering with the interleukin-4 and interleukin-13 pathways. Because COPD is driven by type 2 inflammation, Sanofi and Regeneron Pharmaceuticals had sponsored a study to assess the effectiveness of dupilumab in managing chronic obstructive pulmonary disorder.
935 participants between the ages of 40 and 85 years old were included in this phase 3 clinical trial. These patients had been diagnosed with COPD within the last 12 months and had been treated with the LAMA-LABA combination or the triple therapy of glucocorticoids, LAMA, and LABA for at least 3 months. Patients included in this study had at least two moderate or one severe exacerbations in the previous year that resulted in treatment with systemic glucocorticoids. The mean forced expiratory volume in 1 second (FEV1) of the participants was 1.36 liter, and the usage of bronchodilator improved this mean value to 1.45 liter. Assessment with the 100-point St. George’s Respiratory Questionnaire (SGRQ) yielded an average value of 51.5. The patients were randomly assigned to be treated subcutaneously with either placebo or 300 mg of dupilumab every 2 weeks. After 52 weeks of treatment, the researchers observed that the risk of exacerbation episode occurrence decreased by 34% in those who were treated with dupilumab. In addition, dupilumab increases lung function as evidenced by the increase in FEV1. However, the treatment did not result in significant difference in the SGRQ point.
935 participants between the ages of 40 and 85 years old were included in this phase 3 clinical trial. These patients had been diagnosed with COPD within the last 12 months and had been treated with the LAMA-LABA combination or the triple therapy of glucocorticoids, LAMA, and LABA for at least 3 months. Patients included in this study had at least two moderate or one severe exacerbations in the previous year that resulted in treatment with systemic glucocorticoids. The mean forced expiratory volume in 1 second (FEV1) of the participants was 1.36 liter, and the usage of bronchodilator improved this mean value to 1.45 liter. Assessment with the 100-point St. George’s Respiratory Questionnaire (SGRQ) yielded an average value of 51.5. The patients were randomly assigned to be treated subcutaneously with either placebo or 300 mg of dupilumab every 2 weeks. After 52 weeks of treatment, the researchers observed that the risk of exacerbation episode occurrence decreased by 34% in those who were treated with dupilumab. In addition, dupilumab increases lung function as evidenced by the increase in FEV1. However, the treatment did not result in significant difference in the SGRQ point.